• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

    7/17/23 8:59:00 AM ET
    $LGND
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGND alert in real time by email

    Ligand provides bridge and debtor-in-possession ("DIP") financing to Novan

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (NASDAQ:NOVN) ("Novan") for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand. The transaction is designed to preserve and maximize the value of Novan's commercial business and berdazimer gel development assets. Berdazimer gel is in development for molluscum contagiosum infection, which has a filed new drug application ("NDA") with the Food and Drug Administration ("FDA") with an assigned PDUFA goal date of January 5, 2024. Ligand acquired milestone and royalty rights to berdazimer gel in 2019. If Ligand's bid is the successful bid in the anticipated bankruptcy sale and auction process, Ligand will acquire the Novan assets and consistent with Ligand's business model, will seek to out license or sell the existing development programs and commercial business assets of Novan.

    The terms of the proposed transaction are outlined below:

    • Ligand has submitted a $15 million bid to acquire all the assets of Novan, including berdazimer gel, all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
    • Subject to court approval, Novan will be able to draw down from the $15 million secured DIP loan during the bankruptcy cases (which includes a $3 million bridge financing loan previously extended by Ligand) and will be repaid through the sale of Novan's assets.
    • The $15 million DIP loan will accrue interest at 12% interest annually and will be subject to a 6% increase in interest should Novan default on its loan agreement.
    • Should the court accept a bid for the assets of Novan from another party, Ligand's DIP loan will be repaid, and Ligand expects that its milestone and royalty rights will be preserved.
    • The transaction is expected to close in the third quarter of 2023.

    "In the first half of the year we have focused on fortifying our business team, including a sharpening of our capabilities and expertise in credit, reorganization and operations. We are well positioned to take advantage of opportunities such as the proposed acquisition of Novan's assets," said Todd Davis, CEO of Ligand. "Ligand has a proven track record of finding and investing in attractive assets that are in special situations and maximizing value - both for the assets and for shareholders."

    Matt Korenberg, President and COO of Ligand, added, "We remain confident in the potential of berdazimer gel to be approved, and become an important treatment for molluscum contagiosum. There are currently no FDA-approved prescription drug treatment options for this commonly acquired, highly contagious viral skin disease, and, if approved by the FDA, berdazimer gel would be the first self-application topical treatment for this indication."

    Birch Lake is acting as financial advisor and Morgan Lewis is acting as legal advisor to Ligand for this transaction.

    About Ligand Pharmaceuticals

    Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our platform technologies or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding mid to late-stage drug development in return for economic rights and licensing our technology platforms to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to generate our revenue. We have two primary platform technologies that are available for outlicense – Captisol and Pelican. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. For our Captisol partners, our team supplies the Captisol material needed for their programs. Our Pelican Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

    Follow Ligand on Twitter @Ligand_LGND.

    We use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.

    Forward-Looking Statements

    This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include: the potential that Ligand will provide an additional $12 million in DIP financing to Novan; the timing and outcome of FDA review of Novan's NDA related to berdazimer gel for the treatment of molluscum contagiosum infections; the potential value of Novan's clinical development programs and assets; and statements regarding Novan's bankruptcy proceedings, including whether Ligand's bid will be successful and whether the bankruptcy court will accept the terms of the DIP financing. Actual events or results may differ from Ligand's or its partner's expectations due to risks and uncertainties inherent in Ligand's and its partner's business, including, without limitation: the inherent uncertainties of bankruptcy which gives bankruptcy courts wide latitude to determine the terms of any DIP financing and acquisition bids; the FDA may not approve berdazimer gel for the treatment of molluscum contagiosum infections; Ligand may not be successful in its acquisition bid or, even if successful, may not achieve the anticipated benefits of such acquisition; and other risks described in Ligand's and Novan's prior press releases and filings with the Securities and Exchange Commission available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230717515826/en/

    Get the next $LGND alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LGND
    $NOVN

    CompanyDatePrice TargetRatingAnalyst
    Ligand Pharmaceuticals Incorporated
    $LGND
    4/10/2025$143.00Buy
    Stifel
    Ligand Pharmaceuticals Incorporated
    $LGND
    10/3/2024$135.00Outperform
    Oppenheimer
    Ligand Pharmaceuticals Incorporated
    $LGND
    7/30/2024$130.00Outperform
    RBC Capital Mkts
    Ligand Pharmaceuticals Incorporated
    $LGND
    2/22/2022$180.00 → $130.00Buy
    Benchmark
    Ligand Pharmaceuticals Incorporated
    $LGND
    2/18/2022$185.00 → $165.00Overweight
    Barclays
    Novan Inc.
    $NOVN
    9/24/2021$28.00 → $24.00Buy
    HC Wainwright & Co.
    Ligand Pharmaceuticals Incorporated
    $LGND
    9/22/2021$174.00 → $180.00Overweight
    Barclays
    Ligand Pharmaceuticals Incorporated
    $LGND
    7/30/2021$200.00 → $190.00Buy
    Roth Capital
    More analyst ratings

    $LGND
    $NOVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Participate in May Investor Conferences

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May 20, 2025 at 2:05 p.m. ET and be available for one-on-one meetings.Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 28, 2025.

      5/1/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

      JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

      4/24/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    SEC Filings

    See more

    $LGND
    $NOVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      5/8/25 7:06:37 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ligand Pharmaceuticals Incorporated

      DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      4/22/25 4:09:42 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ligand Pharmaceuticals Incorporated

      DEF 14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      4/22/25 4:07:56 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Ligand Pharma with a new price target

      Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00

      4/10/25 12:42:08 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Ligand Pharma with a new price target

      Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00

      10/3/24 7:34:05 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ligand Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00

      7/30/24 6:24:41 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      8/9/24 5:52:17 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Davis Todd C bought $237,529 worth of shares (4,000 units at $59.38), increasing direct ownership by 6% to 73,090 units

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      9/25/23 4:44:43 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sabba Stephen L exercised 2,406 shares at a strike of $52.30, increasing direct ownership by 8% to 32,584 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      4/16/25 9:34:19 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CLO & Secretary Reardon Andrew was granted 6,415 shares, increasing direct ownership by 23% to 34,783 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      3/6/25 6:55:43 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Espinoza Octavio sold $575,148 worth of shares (5,000 units at $115.03) and was granted 7,484 shares, increasing direct ownership by 10% to 26,363 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      3/6/25 6:55:23 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum

      – Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received conditional acceptance from U.S. FDA for use of KINSOLUS™ as brand name for SB206, if approved – – First New Drug Application (NDA) remains on target with submission expected in Q3 2022 – DURHAM, N.C., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced the appointment of Brian M. Johnson as its Chief Commercial Officer. Additionally, the Company received notice that the U.S. Food and Drug Administration (FDA) has conditionally accepted KI

      11/2/21 8:30:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

      JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

      4/24/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

      3/31/25 7:30:00 AM ET
      $LGND
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    $NOVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      11/1/24 4:07:52 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ligand Pharmaceuticals Incorporated

      SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/14/24 6:26:25 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/13/24 5:08:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care